1   **Distribution, Prevalence of Non-Tuberculous Mycobacteria on Hainan Island and**
2   **Antibiotic Resistance of *Mycobacterium abscessus***

3   Xinru Xu[1#], Jingjing Huang[2#], Hongkun Wang[1], Tianchen Xiang[1], Jun Liu[1], Li Zheng[1*]
4

1. Department of Immunology, Key Laboratory of Tropical Translational Medicine
of Ministry of Education, Hainan Medical University-The University of Hong Kong Joint
Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou,
Hainan, China.
2. Department of Tuberculosis Control and Prevention, Institute for Infectious
Disease Control and Prevention, Hainan Provincial Center for Disease Control and
Prevention, Haikou, Hainan, China.
12

*Correspondence:
Li Zheng (culturelily@sina.com)
[#]These authors contributed equally to this work.

ABSTRACT

Non-tuberculous mycobacteria (NTM) infections are increasingly recognized as a public
health concern, yet their distribution and antibiotic resistance patterns on Hainan Island,
China's tropical hotspot, remain understudied. This study analyzes 158 clinical respiratory
samples from 2015–2018 across 14 cities, identifying 118 NTM isolates from 24 species.
Predominant species include Mycobacterium abscessus (23.73%), M. intracellulare
(22.03%), and M. simiae (14.41%). Spatial mapping reveals elevated prevalence in coastal
areas, with no significant north-south divergence on the island (Bray-Curtis dissimilarity:
0.5954, P = 0.694), but substantial differences from mainland China (North: 0.9604, P =
0.0011; South: 0.9340, P = 0.0013). Antimicrobial testing of M. abscessus isolates
indicates complete resistance to doxycycline (100%), moderate sensitivity to amikacin
(71.4%) and linezolid (50.0%), and variable responses to other agents. Novel detections of
M. algericus and M. sinensis expand Hainan's NTM diversity. These findings establish a
baseline for region-specific surveillance, antibiotic stewardship, and intervention strategies
to combat NTM misdiagnosis and mortality in tropical settings.

IMPORTANCE

Previous studies have not covered the distribution of NTM in various regions of Hainan
province. This study provides the first comprehensive geographic map of NTM in Hainan,
China's tropical island hotspot. By monitoring NTM across 14 cities over four years, we
reveal key patterns in their habitat preferences and dominant species in infections. These
findings establish a foundational framework for region-specific surveillance and treatment
protocols in Hainan and offer a replicable model for global tropical regions combating NTM
infections. Ultimately, this work empowers public health initiatives to reduce misdiagnosis,
enhance antibiotic stewardship, and lower mortality rates among at-risk populations.
40
41   **Keywords:** Non-tuberculous Mycobacteria (NTM); Species Identification; RNA
42   Polymerase Beta Subunit (rpoB); Heat Shock Protein 65 (Hsp65)
43

44   **INTRODUCTION**

Non-tuberculous mycobacteria (NTM), belonging to the Mycobacteriaceae family, ubiquitously inhabit natural environments such as soil, water, and even the human body. With over 200 documented species, of which approximately 60 are pathogenic, these organisms can infect diverse tissues, including skin, soft tissues, lymphatics, synovial fluid, joints, bones, and lungs (1). In immunocompromised individuals, pathogenic NTM can lead to opportunistic NTM pulmonary disease (NTM-PD) and extrapulmonary infections(2). The global incidence of NTM infections has been increasing, particularly in developing countries (3). In China, the prevalence of NTM infections rose from 4.9% in 1990 to 22.9% in 2010, with the proportion of NTM-related lung infections increasing from 4.24% to 12.68% by 2021 (4, 5). Misdiagnosis of NTM as multidrug-resistant tuberculosis or co-infections with other chronic diseases contributes to escalating mortality rates(6, 7). However, due to the absence of mandatory reporting systems for NTM infections in many nations, current epidemiological data is limited and potentially underestimates the actual burden(8, 9). An accurate understanding of NTM epidemiology and the implementation of effective surveillance systems are thus crucial for guiding control strategies.

Most regions in China have established comprehensive monitoring systems and research strategies for NTM, especially in developed areas like Shanghai, Beijing, and Guangdong, which feature extensive temporal coverage, diverse sample collection, and a wealth of NTM subspecies, leading to well-developed theoretical frameworks and even rare identifications (10–14). NTM research of Hainan Island, initiated in 2019(15), has faced challenges such as geographical limitations and insufficient sample diversity, resulting in a significant lag compared to other provinces. This study aims to enhance the breadth and depth of NTM investigation in Hainan, providing a robust foundation for more precise and targeted intervention strategies, ensuring their scientific rigor and effectiveness, and advancing the scientific frontiers in NTM prevention and control.

Mycobacterium avium complex (MAC), the most common slowly growing mycobacteria (SGM), is the predominant cause of NTM pulmonary disease globally(16), with strains like *M. avium*, *M. intracellulare*, *M. chimaera*, *M. marseillense*, *M. bouchedurhonense*, *M. timonense*, *M. yongonense*, and *M. paraintracellulare* recognized as pathogens (17). The *M. abscessus* complex (MABC), dominated by *M. abscessus* subspecies, accounts for 65%-80% of rapidly growing mycobacteria (RGM) pulmonary infections(18) (19), with three key subspecies identified. *M. kansasii* ranks as the second most frequent NTM pathogen in some European countries(20), whereas in China, MAC and MABC prevail, specifically *M. intracellulare* and *M. abscessus*, along with other pathogens such as *M. fortuitum*, *M. gordonae*, and *M. kansasii*. In China, NTM distributions exhibit a southern, coastal, and warm-humid regional predominance over northern, inland, and cold-dry areas(2, 5).

Drug susceptibility testing of numerous NTM isolates indicates clarithromycin (CLR) and amikacin (AMK) as highly effective against MAC, serving as first-line agents. MAC exhibits resistance to linezolid (42.86%) and moxifloxacin (25.32%), positioning these as second-line options.. Avoiding drugs like those initially can prevent ineffective treatment.

MABC exhibits high resistance to moxifloxacin, ciprofloxacin, and tobramycin (>95%), alerting clinicians not to rely on these drugs for treating MABC-related diseases. Instead, the relatively high susceptibility of MABC to tigecycline (98.53%) and amikacin (64.71%) , highlights their potential as first-line therapies(21). This knowledge can prevent the use of ineffective antibiotics, which may waste time and resources and worsen the patient's condition. Given the suboptimal outcomes of current NTM treatments, the exploration of alternative antibiotics such as clofazimine, bedaquiline, delamanid, and tedizolid is warranted. These drugs have shown in vitro activity against specific NTM species, including *M. intracellulare*, *M. avium* (clofazimine-sensitive), *M. abscessus*, *M. fortuitum*, and *M. chelonae* (tedizolid-responsive), highlighting their therapeutic potential (22).

Prevots' research(23) identified atmospheric hydrologic parameters as critical drivers of non-tuberculous mycobacteria (NTM) ecological transmission dynamics, with significant spatial associations between aerosol-phase water loading and pathogen prevalence. In Hainan Island, the observed biogeographic divergence of NTM species clusters across climate gradients underscores the need for region-adapted frameworks to address possible tropical maritime environmental determinants. Previous studies have not covered the distribution of NTM in various regions of Hainan province. We delve into the distribution and antibiotic resistance profiles of NTM in

101 Hainan, elucidating the current NTM prevalence scenario and augmenting the province's NTM
102 research corpus.
103

104 **METHODS**

105 **Ethics Statement**
106 This study was conducted with the approval of the Ethics Committee of Hainan
107 Medical University, under the ethics number HYLL-2021-170.
108

Study Population and Sample Collection
The experimental samples were sourced from the Hainan Tuberculosis Prevention
and Control Institution, covering the period 2015-2018. A total of 158 sputum and
bronchoalveolar lavage fluid specimens, clinically suspected of NTM infection, were
collected from 14 cities and counties in Hainan Island, including Baisha, Baoting,
Changjiang, Chengmai, Danzhou, Ding'an, Dongfang, Haikou, Ledong, Lingao, Lingshui,
Qionghai, Sanya, and Wenchang.
116

Materials and Equipment
Bacterial genomic DNA extraction kit (Tiangen Biotech, Beijing), Template DNA,
buffer, dNTPs, TaqDNA polymerase (Tiangen Biotech, Beijing), Hsp65 and rpoB gene
amplification primers (Tsingke Biotech, Beijing), PCR thermal cycler (Bio-Rad
Laboratories, Shanghai), DNA recovery kit (Tiangen Biotech, Beijing). High-speed
benchtop centrifuge (Eppendorf, Germany).
123

Clinical Sample Collection
Patients were instructed to fast for at least 1-2 hours before sample collection.
Before expectoration, patients perform a mouthwash with 0.1% spirulina solution three
times, followed by rinsing with clean water, to minimize oral flora contamination.
Sputum Production: Deep coughing is encouraged to ensure productive sputum collection
into sterile plastic containers with a screw-mouth, provided by the hospital, emphasizing
the importance of collecting deep sputum such as purulent, mucoid, or blood-streaked
specimens. Saliva samples may also be accepted if no productive sputum can be
produced. Each patient provides three types of sputum samples (morning, night, and on-
site) over a day. Morning and night sputa are self-collected at home, while the on-site
sample is obtained at the hospital. Samples are transported to the tuberculosis laboratory
within 4 hours of collection. If immediate transportation is not feasible, samples are
refrigerated at 4℃ until delivery. In the absence of a provincial tuberculosis control
institute, samples are sent to designated tuberculosis laboratories in each city for initial
testing. Subsequently, positive cultures are forwarded to the Hainan Provincial Center for
Disease Control and Prevention for confirmation and further analysis.
140

PCR-based Species Identification
DNA was extracted from each sample to serve as a template for subsequent PCR
reactions using primers targeting rpoB and Hsp65 genes. Primer sequences were as
follows: Hsp65-F: 5'-ACC AAC GAT GGT GTG TCC AT-3', Hsp65-R: 5'-CTT GTC GAA
CCG CAT ACC CT-3', rpoB-F: 5'- GAC GAC ATC GAC CAC TTC GG -3', rpoB-R: 5'-
GGG GTC TCG ATC GGG CAC AT-3'. Amplification was conducted in 20 µL reaction
mixtures containing 2 µL 10×PCR buffer, 200 µM dNTPs, 0.25 µM of each primer, and 1U
TransTaq HiFi DNA polymerase (Tiangen Biotech, Beijing). Thermal cycling conditions
comprised initial denaturation at 94°C for 5 minutes; 30 cycles of 94°C denaturation for 30
seconds, annealing at 60°C for 30 seconds, extension at 72°C for 1 minute; and a final

extension at 72°C for 10 minutes. Products were analyzed by agarose gel electrophoresis,
and DNA fragments were recovered using a gel extraction kit and sent to Hainan Nanshan
Biotechnology Co., Ltd. for sequencing. Ultimately, nucleotide sequences were aligned
with GenBank references via the NCBI BLAST website on 04/22/2024
(https://blast.ncbi.nlm.nih.gov/Blast.cg).
156
Phylogenetic Tree Construction
To explore evolutionary relationships between Hsp65 and rpoB genes, multiple
sequence alignment was performed using the Muscle algorithm in MEGA software (v11.0)
with default parameters. Neighbor-joining (NJ) method was applied in MEGA to construct
phylogenetic trees. To enhance tree topology reliability, a bootstrapping process involving
1000 iterations was executed. For intuitive comprehension, the phylogenetic tree was
refined and annotated using the Tree Visualization by One Table (TvBOT,
https://www.chiplot.online/tvbot.html, version 2.6) online tool.
165
Drug Sensitivity Test
According to Clinical and Laboratory Standards Institute (CLSI) guidelines, broth
microdilution assays were employed for in vitro antimicrobial susceptibility testing of
selected NTM isolates. Minimum inhibitory concentration (MIC) values require clinical
context interpretation and adjustment. MIC50 is defined as the lowest concentration of the
drug that inhibits the growth of 50% of the tested M. abscessus isolates; MIC90 is the
lowest concentration that inhibits 90% of the tested *M. abscessus* isolates. The MIC
breakpoints used to define susceptibility categories are based on the Clinical and
Laboratory Standards Institute (CLSI) guidelines, specifically the M24-A2 document, with
the exception of azithromycin. For amikacin, linezolid, moxifloxacin, and doxycycline, the
breakpoints are as follows: Amikacin: Susceptible (S) ≤ 16 µg/ml, Intermediate (I) 32
µg/ml, Resistant (R) ≥ 64 µg/ml. Linezolid: S ≤ 8 µg/ml, I 16 µg/ml, R ≥ 32 µg/ml;
Moxifloxacin: S ≤ 1 µg/ml, I 2 µg/ml, R ≥ 4 µg/ml; Doxycycline: S ≤ 1 µg/ml, I 2 - 4 µg/ml, R
≥ 8 µg/ml. These breakpoints are based on CLSI M24 - A2(24). For azithromycin, the
breakpoints (S ≤ 2 µg/ml, I 4 µg/ml, R ≥ 8 µg/ml) are derived from Li,2017(25), as there is
no direct CLSI breakpoint for this drug against M. abscessus.
182
183 The MicroDST™ system (Yinked AUTOBIO Diagnostics Co., Ltd., Zhuhai, China)
184 was utilized for resistance testing of NTM isolates. MIC breakpoints and
185 sensitivity/resistance determination were interpreted per manufacturer instructions. Five
186 antibiotics were tested against *M. abscessus* isolates: moxifloxacin, amikacin, linezolid,
187 azithromycin, and doxycycline.
188
189 **Data Analysis**
190
Bray-Curtis dissimilarity matrices were computed via the vegdist function (vegan
package in R) after data preprocessing (removing all-zero species/samples, transposing
matrices). Permutational Multivariate Analysis of Variance (PERMANOVA) was conducted
to test for significant differences in NTM species composition between regions using
adonis2 with 9999 permutations. A non-parametric bootstrap (10000 replications) with the
bias-corrected and accelerated (BCa) method estimated the 95% confidence interval for
the mean inter-group Bray-Curtis distance.

RESULTS
NTM Subspecies Characterization

From 158 clinical samples suspected of NTM collected between 2015 and 2018,157 isolates were successfully species-identified, comprising 118 NTM (across 24 species) and 39 non-NTM organisms. Identification primarily relied on rpoB gene sequencing, with Hsp65 sequencing serving as a supplementary tool for conclusive determination. All data have been uploaded to https://nmdc.cn/submit/dashboard：Hsp65 (NMDCN0007ON9 to NMDCN0007OQQ) and rpoB (NMDCN0007OQR to NMDCN0007OUG). The species distribution, as shown in Figure 1, was led by *M. abscessus* (28/118, 23.73%), *M. intracellulare* (26/118, 22.03%), *M. simiae* (17/118, 14.41%), *M. paraintracellulare* (16/118, 13.56%), and *M. colombiense* (5/118, 4.24%). MTB(23), *Nocardia thailandica* (3/16, 18.75%), *Tsukamurella paurometabola* (2/16, 12.5%), and *Gordonia jinghuaiqii* (2/16, 12.5%), were also identified. Detailed composition ratios are illustrated in Table 1.

Table 1 NTM species identified from 2015 to 2018 in Hainan, China

		Year				
		2015	2016	2017	2018	Total
Clinical samples		1769	318	327	468	2882
NTM*	Total	73	7	13	25	118
	M. abscessus	16	-	3	9	28
	M. intracellulare	12	2	4	8	26
	M. simiae	9	2	2	4	17
Others	Total	6	-	3	7	16
	Gordonia jinghuaiqii	1	-	-	1	2
	Actinomadura verrucosospora	1	-	-	-	1
	Gordonia hongkongensis	1	-	-	-	1
	Nocardia thailandica	1	-	2	-	3
	Gordonia aichiensis	2	-	-	-	2
	Tsukamurella paurometabola	-	-	-	2	2
	Nocardia nova	-	-	-	1	1
	Corynebacterium tuberculostearicum	-	-	1	-	1
	Gordonia otitidis	-	-	-	1	1
	Corynebacterium kroppenstedtii	-	-	-	1	1
	Streptomyces tubbatahanensis	-	-	-	1	1
TB(Missing)	Total	18	3	1	1	23

*Only the top three subspecies in terms of the number of NTMs are displayed

rpoB Gene Phylogeny of NTM

A neighbor-joining (NJ) phylogenetic tree, based on NTM rpoB sequences, revealed distinct clustering patterns among pathogenic and potentially pathogenic species. *M. fortuitum* and *M. abscessus* grouped into a distinct cluster of rapidly growing, pathogenic mycobacteria. Strong bootstrap support validated the tree's reliability, with *M. sherrisii* and *M. simiae* closely related per Hsp65 and rpoB analysis, reflecting proximity to MAC, MABC, and *M. simiae* complexes(Figure 2). Hsp65 Gene Phylogeny of NTM was shown in Supplemental Figure 1.

Spatial Distribution of NTM in Hainan Island

The 118 NTM isolates were distributed across 14 cities in Hainan, with distinct
patterns. Northeastern regions reported higher NTM presence compared to southwestern,
and SGMs outnumbered RGMs. MAC and MABC were dominant NTM groups, featuring
M. intracellulare and *M. abscessus* respectively. SGMs were detected in all except
Baoting, while RGMs were absent in Chengmai and Baisha. Key distributions included *M.*
intracellulare in Qionghai, Lingshui, Dongfang, and Danzhou, and *M. abscessus* in Dingan,
Wenchang, and Haikou. Species like *M. algericus*, *M. sinensis*, *M. bacteremicum*, and
others showed unique distributions. Refer to Figure 3 for comprehensive mapping.
229
230   Regional Comparison
231
Bray-Curtis dissimilarity analysis revealed three distinct epidemiological clusters
(Table 2). Intra-island variation: The northern and southern regions of Hainan Island
demonstrated moderate microbial differentiation (BC = 0.5954, *P* = 0.694), which indicates
that the difference in the NTM strain communities between the northern and southern parts
within Hainan Province is not significant (Details in TABLE S1). Inter-regional divergence:
Striking contrasts emerged between Hainan Island and mainland China, with the
dissimilarity between Hainan and North China reaching 0.9604 (P =0.0011). Hainan-South
China dissimilarity measured 0.9340 (*P* = 0.0013) (Details in TABLE S2).

Table 2 Bray-Curtis Dissimilarity Analysis of NTM Strain

Region Comparison	Bray-Curtis Distance	*P*	95%CI
Northern Hainan vs. Southern Hainan	0.5954	0.694	[0.5234, 0.6672]
North (CHINA)(26–28)vs. Hainan	0.9604	0.0011	[0.9491, 0.9688]
South (CHINA)(29–31) vs. Hainan	0.9340	0.0013	[0.9124, 0.9499]

241   Susceptibility Test Results of *M. abscessus*

242   The MICs and breakpoints for seven antibiotics against 28 *M. abscessus* isolates are
243 detailed in Table 3. The isolates displayed high levels of antibiotic resistance, with
244 universal resistance to doxycycline but retained sensitivity to amikacin (71.4%) and
245 linezolid (50.0%). Complete resistance and sensitivity profiles are elaborated in Table 3.

Table 3 Drug susceptibility test of *M.abscessus* （n=28）

Antimicrobial agent	MIC(µg/mL)						Number(%)		
	MIC range	MIC 50	MIC 90	S	I	R	S	I	R
Amikacin	<1-64	4	64	≤16	32	≥64	(20/28)71.4%	(3/28)10.7%	(5/28)17.9%
Linezolid	2-32	8	32	≤8	16	≥32	(14/28)50.0%	(8/28)28.6%	(6/28)21.4%
Moxifloxacin	0.125-16	4	16	≤1	2	≥4	(8/28)28.6%	(6/28)21.4%	(14/28)50.0%
Azithromycin	<1-32	16	32	≤2	4	≥8	(9/28)32.1%	(5/28)17.9%	(14/28)50.0%
Doxycycline	16->128	>128	>128	≤1	2~4	≥8	0	0	(28/28)100%

246
247 **DISCUSSION**

This study identified five major groups of NTM: MAC, MABC, *M. simiae* complex, *M. fortuitum* complex, and other NTM species. MAC, a common causative agent of human NTM diseases affecting various organs such as lungs, soft tissues, lymph nodes, and bone marrow, with MAC pulmonary disease being the most prevalent(21), was also the primary NTM pathogen detected in our study from pulmonary disease cases in Hainan, with a total of 51 isolates (comprising *M. intracellulare, M. paraintracellulare, M. colombiense, M. timonense, M. avium*). This aligns with previous reports by Zhong (15) and Wang (21) who identified 149 and 154 MAC isolates respectively, reinforcing the widespread distribution of MAC in Hainan. MABC, another dominant NTM group, predominantly consisted of *M. abscessus* and its subspecies, differing slightly from Zhong and Wang's findings where *M. intracellulare* was more frequency. *M. simiae* complex emerged as the third most frequent NTM in Hainan, further supporting its presence as a significant species in the region, contrasting its less frequent detection in other provinces(2). The NTM profile in Hainan generally aligns with previous studies by Zhong (15, 32),Wang(21),and Wu(33), showing a higher prevalence of SGMs compared to RGMs. Huang(34) in Beijing also found *M. intracellulare* as the dominant NTM, followed by *M. abscessus* and *M. avium*, mirroring our results where *M. abscessus* and *M. intracellulare* dominate.

No statistically significant difference in NTM strain composition was observed between northern and southern Hainan Island. This similarity is driven by two key factors: both regions share a tropical monsoon climate, lacking sufficient climatic variability to drive NTM species differentiation; human activity patterns are highly uniform, with tourism and tropical agriculture dominating economic activities; and no significant social drivers exist to influence NTM transmission dynamics. However, this study identified Danzhou as the region with the highest NTM isolation frequency, contrasting with earlier studies (2015–2018) that reported Haikou as the primary hotspot(15). This discrepancy arises from methodological advancements, in which our use of Hsp65 and rpoB gene sequencing, combined with GenBank sequence alignment, enabled precise identification of NTM subspecies, Mycobacterium tuberculosis (MTB), and contaminating bacteria, unlike prior studies that relied on gene chip technology limited to detecting 17 common mycobacterial species. These improvements enhance the thoroughness and reliability of our findings.

A marked difference in NTM strain composition was observed between northern mainland China(26–28) and Hainan Island (BC = 0.9604), reflecting distinct regional NTM profiles. In Hainan, M. abscessus predominates, favored by the region's hot, humid tropical climate, which is less suitable for M. intracellulare, the dominant NTM in northern China's drier environments, such as Beijing(26), where it accounts for 40–60% of isolates(35). Northern regions typically exhibit a higher prevalence of slow-growing mycobacteria (SGM), with M. intracellulare as a key representative, compared to rapidly growing mycobacteria (RGM) like M. abscessus. Additionally, regional disparities extend to less common species: Mycobacterium lentiflavum, the second most frequently isolated NTM in Tianjin, was absent in Hainan, underscoring the geographic specificity of NTM distributions across China.

Significant differences in NTM strain composition were also found between southern mainland China(29–31) and Hainan Island (BC = 0.9340). In southern China(36), *M. abscessus* is predominance, consistent with its dominance in Hainan, where it was the most frequently isolated NTM. However, species such as *M. kansasii* and *Mycobacterium smegmatis*, detected elsewhere in China, were absent in Hainan. In contrast, *M. avium* predominates in regions like Sichuan(37) and coastal southeastern provinces, e.g., Fujian(38), Zhejiang(39), Jiangsu(40), where it is more frequently isolated than in Hainan, which reported only one single M. avium isolate. These findings highlight Hainan's unique NTM assemblage, shaped by its distinct environmental and geographic characteristics, distinguishing it from both northern and southern mainland China.

Considering Hainan and Taiwan's insular geography and similar latitudes, comparing NTM distributions reveals insights. Huang et al. (41) found *M. abscessus* and MAC to be the most common in Taiwan's NTM-pulmonary infections, mirroring Hainan's MAC dominance and *M. abscessus* prevalence. Although no significant statistical difference was found, subtle variations may exist and warrant further investigation.Hainan's northern NTM abundance contrasts with Taiwan's southern predominance, possibly influenced by Hainan's latitude, tropical/subtropical climates, and topography. Hainan's central mountainous terrain might influence coastal NTM prevalence, reflecting the island's central-high and peripheral-low geography. Overall, these

findings underscore the impact of geographical and environmental factors on NTM distribution
patterns across regions.
As opportunistic pathogens, NTM typically invade organs such as the lungs, skin, lymph
nodes, and bones when host immunity is compromised, with lung infections being most
common(42, 43). Although NTM exhibits lower virulence and pathogenicity than MTB, their non-
specific clinical symptoms and radiological similarities to MTB lead to diagnostic challenges. Their
natural and acquired drug resistance further complicates clinical management(43) underscoring
the importance of NTM species identification and epidemiological investigations.
In Hainan, the hot and humid environment fosters NTM survival and dissemination, making
epidemiological studies in this high NTM-endemic region crucial for local control efforts. Given *M.*
abscessus's natural and acquired resistance to many common antibiotics, resistance testing to
identify effective treatments is essential; clinical practice often employs anti-tubercular drugs(44).
Guidelines(45) recommend clarithromycin, azithromycin, amikacin, and cefoxitin for *M. abscessus*.
Our susceptibility tests revealed rates of 71.4% for amikacin, 50.0% for linezolid, 32.1% for
azithromycin, and 28.6% for moxifloxacin. The high resistance to doxycycline (100%) highlights the
need for caution when using this drug clinically. The intrinsic resistance mechanisms of *M.*
abscessus include its waxy, opaque cell wall, drug transport systems, antibiotic modification, and
target gene polymorphisms(46). Subspecies differences in resistance rates (47), particularly with
higher clarithromycin resistance in *M. abscessus subsp. abscessus* than *subsp. massiliense*,
indicating a need for further study to guide treatment.
Comparative phylogenetic analysis reveals distinct evolutionary trajectories between Hsp65
and rpoB genes in nontuberculous mycobacteria (NTM): The Hsp65 tree exhibits uniform topology
with conserved sequence architecture ideal for resolving macroevolutionary relationships(48),
whereas the rpoB phylogeny displays accelerated evolutionary rates and intricate branching
patterns that facilitate high-resolution discrimination of closely related strains(49). Hsp65-based
phylogenetic analysis demonstrated limited resolution in differentiating *Mycobacterium*
intracellulare from *M. paraintracellulare*, resulting in misidentification of 16/49 (32.7%) *M.*
paraintracellulare strains as *M. intracellulare*. In contrast, rpoB gene sequencing achieved
unambiguous discrimination between these two species. Both phylogenetic trees revealed close
evolutionary proximity between *M. sherrisii* and *M. simiae*, though with divergent statistical support:
strong bootstrap values (0.95) in the Hsp65 tree versus moderate support (0.45) in the rpoB
phylogeny, indicating Hsp65's superior discriminative capacity for this species pair. Notably, weak
bootstrap support (for the *M. sherrisii–M. simiae* clade in the rpoB tree) does not invalidate their
inferred evolutionary relationship, as this conclusion is corroborated by two complementary lines of
evidence: (1) strong nodal support (0.95) for the same clade in the Hsp65 phylogeny;(2) ≥99%
rpoB sequence identity between our isolates and the GenBank-retrieved type strains of *M.*
sherrisii and *M. simiae*. This necessitates critical awareness during diagnostic interpretation to
prevent taxonomic misclassification(50). The rpoB phylogeny further resolved evolutionary
relationships within the MAC(51), demonstrating shared ancestral origins (bootstrap: 0.4-1.0)
among *M. intracellulare*, *M. paraintracellulare*, *M. timonense*, *M. colombiense*, and *M.*
marseillense. This phylogenetic evidence corroborates rpoB's diagnostic reliability for MAC species
delineation, aligning with established multilocus sequence analysis benchmarks. Phylogenetic
discordance is observed in rpoB-based clustering of four Mycobacteroides abscessus isolates from
Danzhou, which segregate into two distinct clades with robust nodal support (Clade A: 1 isolate,
bootstrap=0.98; Clade B: 3 isolates, bootstrap=0.93), despite exhibiting identical mean pairwise
distance (0.01 substitutions/site). This polyphyletic clustering suggests ecological selection
pressures have driven substantial genomic divergence while maintaining taxonomic coherence
under current species delineation criteria.
In recent years, the increasingly widespread whole-genome sequencing (WGS) — a high-
precision tool for identifying and characterizing mycobacteria — outperforms techniques like
targeted PCR genotyping with superior resolution, enabling differentiation of NTM subspecies into
specific clades, providing comprehensive genomic data, and offering unparalleled accuracy in
detecting genetic variations, identifying new species, and predicting virulence genes, thus
underpinning targeted therapy(52, 53).
The study unexpectedly identified numerous non-NTM species, including previously
undetected MTB and species of Corynebacterium, Actinomadura, Gordonia, Tsukamurella,
Streptomyces, and Nocardia, all belonging to the actinobacteria phylum. Streptomyces

tubbatahanensis, not previously reported in China, suggests new perspectives in streptomycete pathogenesis. Tsukamurella paurometabola, rarely pathogenic but previously isolated in Hainan (21) indicates its opportunistic nature. Nocardia species, ubiquitous yet some highly pathogenic especially in immunocompromised individuals, with Nocardia nova known as the second most prevalent (54), and is known to cause pulmonary infections, while *Nocardia thailandica* has also been documented to induce pneumonia(55). Gordonia species, isolated from various environments, can cause opportunistic infections in immunocompromised hosts. Corynebacterium tuberculostearicum is omnipresent on human skin, yet its health impacts require further investigation(56). Definitive differentiation between contamination and bona fide infection necessitates additional iterative sampling and molecular typing, thereby highlighting the imperative of expanding pathogen surveillance in complex clinical scenarios.

Between 2015 and 2018, the present study documented that Mycobacterium abscessus persisted as the dominant species, without notable alterations. Following the nationwide rollout of Xpert MTB/RIF® (Cepheid) nucleic acid amplification testing in 2016, clinical laboratories systematically discontinued routine submission of acid-fast bacilli (AFB) smear-negative specimens to tuberculosis lab for confirmatory culture. Consequently, the sample size decreased. 2015 data reflects pre-intervention sampling, while subsequent years show the impact of policy changes.

As an expansion and deepening of previous work in Hainan, this study leverages the province-wide TB control network for multi-dimensional NTM testing, achieving notable progress in geographic coverage and species diversity. By involving hospitals at all levels and standardizing specimen submission, a comprehensive and representative NTM repository was established, surpassing single-center biases and enhancing sample representativeness. This collaborative, cross-regional approach lays a firm foundation for elucidating regional NTM patterns and potential epidemiological rules. It also underscores the direct influence of public health policies on monitoring activities, emphasizing the need for flexibility and adaptability in future surveillance systems to accurately track NTM epidemiology. Collectively, this study enriches Hainan's NTM epidemiological data, informing targeted control strategies, and highlighting the value of interdisciplinary and inter-institutional cooperation in addressing NTM public health challenges.

CONCLUSION

This study has provided an in-depth exploration into the geographic distribution and drug resistance patterns of NTM in Hainan Island, highlighting *M. abscessus* and MAC as principal pathogens driving NTM infections in the region, predominantly in Danzhou, Qionghai, Dingan. Novel findings include the documentation of previously unreported NTM species in Hainan, specifically *M. novum*; *M. algericus*; *M. conceptionense*; *M. vanbaalenii*; *M. eburneum*; *M. nebraskense*; *M. sinensis*; *M. bacteremicum*; *M. frederiksbergense*; *M. phlei.* Moreover, the study underscores the therapeutic potential of amikacin and linezolid against *M. abscessus*.

FUNDING

This study was supported by the Natural Science Foundation of Hainan Province (No:821QN0893, No: 820QN274), the Natural Science Project of Hainan Provincial Department of Education (No: Hnky2022-38, No: Hnky2020-38), and Hainan Provincial Health Commission Joint Project for Science and Technology Innovation in Health (No: WSJK2024MS191). We acknowledged support from the Innovation and Entrepreneurship Training Program for College Students of Hainan Medical University (No: S202511810034, No: X202511810063).

DATA AVAILABILITY

All sequencing data generated in this study have been deposited in the National Microbiology Data Center of China. The sequencing results of Hsp65 genes have been assigned accession numbers ranging from NMDCN0007ON9 to NMDCN0007OQQ, and rpoB genes from NMDCN0007OQR to NMDCN0007OUG.

411 **AUTHOR CONTRIBUTION**

412   XX, HW, and TX conducted the experiments; JH was responsible for sample collection; XX,
413 JL, and JH performed the data analysis; XX and LZ wrote and revised the manuscript; LZ designed
414 the study.

REFERENCES

1. Mortaz, E., Moloudizargari, M., Varahram, M., Movassaghi, M., Garssen, J., Kazempour Dizagie, M., Mirsaeidi, M., Adcock, I. M. 2018.What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections?. *Iranian journal of allergy, asthma, and immunology 17*(2), 100–109.
2. Yu X, Liu P, Liu G, Zhao L, Hu Y, Wei G, Luo J, Huang H. 2016. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. *Journal of Infection* 73:558-567.
3. Stout JE, Koh W-J, Yew WW. 2016. Update on pulmonary disease due to non-tuberculous mycobacteria. *International Journal of Infectious Diseases* 45:123-134.
4. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, Chen M, Zhao Y, Jiang S, Du X, He G, Li J, Wang S, Chen W, Xu C, Huang F, Liu X, Wang Y. 2014. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. *The Lancet* 383:2057-2064.
5. Sun Q, Yan J, Liao X, Wang C, Wang C, Jiang G, Dong L, Wang F, Huang H, Wang G, Pan J. 2022. Trends and Species Diversity of Non-tuberculous Mycobacteria Isolated From Respiratory Samples in Northern China, 2014–2021. *Frontiers in Public Health* 10:923968.
6. Veziris N, Andréjak C, Bouée S, Emery C, Obradovic M, Chiron R. 2021. Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study. *BMC Infectious Diseases* 21(1):1165.
7. Gopalaswamy R, Shanmugam S, Mondal R, Subbian S. 2020. Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. *Journal of Biomedical Science* 27(1):74.
8. López-Roa P, Aznar E, Cacho J, Cogollos-Agruña R, Domingo D, García-Arata M, Millán R, Páez M, Perez-Cecilia E, Ruiz-Serrano M, Simón M, Tato M, Toro C, Valverde J, Esteban J. 2020. Epidemiology of Non-Tuberculous Mycobacteria isolated from clinical specimens in Madrid, Spain, from 2013 to 2017. *European Journal of Clinical Microbiology & Infectious Diseases* 39:1089-1094.
9. Zhang H, Luo M, Zhang K, Yang X, Hu K, Fu Z, Zhang L, Wu P, Wan D, Han M, Wang X. 2020. Species identification and antimicrobial susceptibility testing of non-tuberculous mycobacteria isolated in Chongqing, Southwest China. *Epidemiology and Infection* 149:e7.
10. Luo L, Liang L, Zhang R, Chen W, Yu F, Zhao Y, Yue J. 2022. Using Vitek MS v3.0 To Identify Nontuberculous Mycobacteria in Liquid Media in a Clinical Microbiology Laboratory. *Microbiology Spectrum* 10(6):e0201822.
11. Le Cai Ji SC Wei Piao,Chuang Yue Hong,Jin Li Li,Qi Jiang. 2022. Increasing Trends and Species Diversity of Nontuberculous Mycobacteria in A Coastal Migrant City-Shenzhen, China. *Biomedical and environmental sciences : BES* 35:146-150.
12. Liu Q, Du J, An H, Li X, Guo D, Li J, Gong W, Liang J. 2023. Clinical characteristics of patients with non-tuberculous mycobacterial pulmonary disease: a seven-year follow-up study conducted in a certain tertiary hospital in Beijing. *Frontiers in Cellular and Infection Microbiology* 13:1205225.
13. Zhang Q, Xiao H, Yan L. 2021. PCR-reverse blot hybridization assay in respiratory specimens for rapid detection and differentiation of mycobacteria in HIV-negative population. *BMC Infectious Diseases* 21(1):264.
14. Huang J, Li Y, Zhao Y, Yang W, Xiao M, Kudinha T, Xu Y. 2020. Prevalence of nontuberculous mycobacteria in a tertiary hospital in Beijing, China, January 2013 to December 2018. *BMC Microbiology* 20(1):158.

15. Zhong Y, Lin M, Lin C, Chen Z, Zheng W, Pei H. 2019. Characteristics of non-
tuberculous Mycobacterial infection in suspected tuberculosis patients in Hainan area.
Chinese Journal of Infection Control 18:701-707.
16. Prevots DR, Marras TK. 2015. Epidemiology of Human Pulmonary Infection with
Nontuberculous Mycobacteria. *Clinics in Chest Medicine* 36:13-34.
17. Li Y. 2021. Master thesis. Analysis of the Subspecies Identification and the Correlation
between the Phenotype and Genotype of Mycobacterium Avium Complex. Ministry of
Health Beijing Geriatric Medical Research Institute, Beijing.
18. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM,
Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF,
Wallace RJ, Winthrop K. 2007. An Official ATS/IDSA Statement: Diagnosis, Treatment,
and Prevention of Nontuberculous Mycobacterial Diseases. *American Journal of
Respiratory and Critical Care Medicine* 175:367-416.
19. Guo Q, Chu H, Ye M, Zhang Z, Li B, Yang S, Ma W, Yu F. 2018. The Clarithromycin
Susceptibility Genotype Affects the Treatment Outcome of Patients with
Mycobacterium abscessus Lung Disease. *Antimicrobial Agents and Chemotherapy*
62(5):e02360-17.
20. Hoefsloot W, Ingen J van, Andrejak C, Ängeby K, Bauriaud R, Bemer P, Beylis N,
Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley
CL, Dekhuijzen PNR, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M,
Folkvardsen DB, Gibbons N, Gómez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh
P-R, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh W-J, Lange
B, Leao S, Macedo R, Mannsåker T, Marras TK, Maugein J, Milburn HJ, Mlinkó T,
Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Peña M, Piersimoni C,
Polanová M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, Silva MP da, Simsek H,
Soolingen D van, Szabó N, Thomson R, Fernandez TT, Tortoli E, Totten SE, Tyrrell G,
Vasankari T, Villar M, Walkiewicz R, Winthrop KL, Wagner D. 2013. The geographic
diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-
NET collaborative study. *European Respiratory Journal* 42:1604-1613.
21. Wang J, Chen Z, Xu Y, Qiu W, Chen S, Pei H, Zhong Y. 2023. Screening and Drug
Resistance Analysis of Non-Tuberculous Mycobacteria in Patients with Suspected
Pulmonary Tuberculosis on the Hainan Island, China. *Infection and Drug Resistance
Volume* 16:463-476.
22. Huang W-C, Yu M-C, Huang Y-W. 2020. Identification and drug susceptibility testing for
nontuberculous mycobacteria. *Journal of the Formosan Medical Association* 119:S32-
S41.
23. Prevots DR, Adjemian J, Fernandez AG, Knowles MR, Olivier KN. 2014.
Environmental Risks for Nontuberculous Mycobacteria. Individual Exposures and
Climatic Factors in the Cystic Fibrosis Population. *Annals of the American Thoracic
Society* 11:1032-1038.
24. Clinical and Laboratory Standards Institute. 2011. M24-A2 susceptibility testing of
mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. 2nd
ed
25. Li G, Pang H, Guo Q, Huang M, Tan Y, Li C, Wei J, Xia Y, Jiang Y, Zhao X, Liu H, Zhao
L, Liu Z, Xu D, Wan K. 2017. Antimicrobial susceptibility and MIC distribution of 41
drugs against clinical isolates from China and reference strains of nontuberculous
mycobacteria. *International Journal of Antimicrobial Agents* 49:364-374.
26. Zhang J, Su J, Ding B, Liu J, Yi J, Yang X, Wang N, Wang S. 2017. Distribution and
drug resistance of nontuberculous Mycobacteria in Beijing. Chinese Journal of
Tuberculosis and Respiratory Diseases 40:210-214.

27. Tan J, Wang Y, Li Z, Xia S, Guo Z, Li W, Yuan Y, Gao J, Wang W. 2024. Laboratory
tests and analysis of drug resistance in non-tuberculous mycobacteria. *Heliyon*
10:e28665.
28. Zhao H, Ju H, Wang Z, Jiang L, Sun R, Zhang G, Li X, Wang C. 2024. Identification of
non-tuberculous mycobacteria from 2021 to 2022 in a center of Tianjin. *Journal of*
Tropical Medicine 24:1620-1625.
29. Chen X, Qiu D, Shen W, Zhu Y. 2023. Analysis of epidemic states and distribution
characteristics of non — tuberculous Mycobacteria in Taizhou City. *Chinese Journal*
of Health Laboratory Technology 33:536-538.
30. Wu Y, Li Q, Jia Q, Huang Y, Bai X, Cheng Q. 2025. Identification and drug resistance
analysis of non-tuberculous mycobacterial pulmonary disease pathogens in suburban
areas of Hangzhou. *Journal of Tuberculosis and Lung Disease* 420-425.
31. Lin S, Wei S, Zhao Y, Lin J, Pang Y. 2019. Epidemiology Of Human Pulmonary
Infection With Nontuberculous Mycobacteria In Southeast China: A Prospective
Surveillance Study. *Infection and Drug Resistance Volume* 12:3515-3521.
32. Zhong Y, Chen Z, Wang J, Lin M, Xu Y, Pei H. 2022. Species identification of non-
tuberculous Mycobacteria from patients with pulmonary infection in Hainan. *Disease*
Surveillance 37:1053-1058.
33. Wu H, Weng M, Liu R, Zhou G, Li W. 2024. Epidemiological status and clinical
characteristics of 225 cases of non-tuberculous mycobacterial pulmonary disease in
Hainan Province. *China Tropical Medicine* 24:463-467.
34. Huang J, Li Y, Zhao Y, Yang W, Xiao, M, Kudinha T, Xu Y. 2020. Prevalence of
nontuberculous mycobacteria in a tertiary hospital in Beijing, China, January 2013 to
December 2018. *BMC microbiology* 20(1):158.
35. Tang L. 2019. Current status and research progress of the identification of
nontuberculous mycobacterial species. *Chronic Pathematology Journal* 20:831-834.
36. Xu N, Li L, Wu S. 2024. Epidemiology and laboratory detection of non-tuberculous
mycobacteria. *Heliyon* 10(15):e35311.
37. Yang J, Li T, Yang C, Chen Y, Ye G. 2020. Distribution and drug resistance of non-
tuberculous mycobacteria in the skin and soft tissue infections. *Chinese Journal of*
Laboratory Diagnosis 24:1266-1268.
38. Huang M, Lin Y, Chen X, Wu D. 2021. The value of gene chip detection of
bronchoalveolar lavage fluid in the diagnosis of nontuberculous mycobacterial lung
disease. *Annals of Palliative Medicine* 10:6438-6445.
39. Zhu Y, Hua W, Liu Z, Zhang M, Wang X, Wu B, Wang Z, Chen J. 2022. Identification
and characterization of nontuberculous mycobacteria isolated from suspected
pulmonary tuberculosis patients in eastern china from 2009 to 2019 using an
identification array system. *The Brazilian Journal of Infectious Diseases* 26:102346.
40. Hu C, Huang L, Cai M, Wang W, Shi X, Chen W. 2019. Characterization of non-
tuberculous mycobacterial pulmonary disease in Nanjing district of China. *BMC*
Infectious Diseases 19(1), 764.
41. Huang H, Cheng M, Lu P, Shu C, Wang J, Wang J, Chong I, Lee L. 2017.
Epidemiology and Predictors of NTM Pulmonary Infection in Taiwan - a Retrospective,
Five-Year Multicenter Study. *Scientific Reports* 7(1), 16300
42. Dastranj M, Farahani A, Shahraki AH, Atashi S, Mohajeri P. 2017. Molecular
identification and distribution of non-tuberculous mycobacteria isolated from clinical
specimens by PCR-sequencing method in West of Iran. *The Clinical Respiratory*
Journal 12:996-1002.
43. Yang X, Zhao Y, Yi J, Chen H, Chen S, Dai X, Ding B, Sun S, Li C. 2022. Analysis of
risk factors and drug resistance of clinical isolates of non-tuberculous mycobacteria in
Beijing prevention and control institutions in 2019. *Journal of Clinical Pulmonary*
Medicine 27:1148-1153.

44. Wang D, Lin W, Cheng H, Bao X, Xu D, Liang S, Jiang Y, Wang C. 2022. Clinical
Characteristics and Antimicrobial Susceptibility of Mycobacterium intracellulare and
Mycobacterium abscessus Pulmonary Diseases: A Retrospective Study. Canadian
Journal of Infectious Diseases and Medical Microbiology 2022:1-9.
45. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC,
Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK,
Olivier KN, Santin M, Stout JE, Tortoli E, Ingen J van, Wagner D, Winthrop KL. 2020.
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official
ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. *Clinical Infectious Diseases*
71:905-913.
46. Lopeman R, Harrison J, Desai M, Cox J. 2019. Mycobacterium abscessus:
Environmental Bacterium Turned Clinical Nightmare. *Microorganisms* 7:90.
47. Wang X.2023. Master thesis. Subspecies distribution and drug resistance
characteristics of Mycobacterium abscessus complex clinical isolates. Guangzhou
Medical University, Guangzhou.
48. Pascapurnama DN, Zavitri N, Koesoemadinata R, Cahyadi AI, Chaidir L. 2023.
Identification of Significant Pathogenic Nontuberculous Mycobacteria Species from
Presumptive TB Patients Using Partial hsp65 Gene Sequencing. *Infection and Drug*
Resistance Volume 16:6923-6930.
49. Kim B-J, Lee S-H, Lyu M-A, Kim S-J, Bai G-H, Kim S-J, Chae G-T, Kim E-C, Cha C-Y,
Kook Y-H. 1999. Identification of Mycobacterial Species by Comparative Sequence
Analysis of the RNA Polymerase Gene (*rpoB*). *Journal of Clinical Microbiology*
37:1714-1720.
50. Borroni E, Badoum G, Cirillo DM, Matteelli A, Moyenga I, Ouedraogo M, Roggi A,
Saleri N, Tagliani E, Tortoli E. 2015. *Mycobacterium sherrisii* Pulmonary Disease,
Burkina Faso. *Emerging Infectious Diseases* 21:2093-2094.
51. Tuberculosis Branch of Chinese Medical Association. 2020.Guidelines for the
diagnosis and treatment of nontuberculous mycobacterial diseases. Chinese Journal
of Tuberculosis and Respiratory Diseases 43:918-946.
52. Dohál M, Porvazník I, Solovič I, Mokrý J. 2021. Whole Genome Sequencing in the
Management of Non-Tuberculous Mycobacterial Infections. *Microorganisms* 9:2237.
53. Turenne CY. 2019. Nontuberculous mycobacteria: Insights on taxonomy and evolution.
Infection, Genetics and Evolution 72:159-168.
54. Bruce CN, Esmaili N. 2023. Periocular Infection With Nocardia nova Following
Dacryocystorhinostomy With Silicone Stent Intubation. *Ophthalmic Plastic and*
Reconstructive Surgery 39:e202-e204.
55. Effendi M, Tirmizi S, McManus D, Huttner AJ, Peaper DR, Topal JE. 2021. Nocardia
thailandica Brain Abscess in an Immunocompromised Patient. *Case Reports in*
Infectious Diseases 2021:1-4.
56. Nashwa M.Ahmed P ClaytonDeming,Katherine P Lemon,Heidi H Kong,Julia A
Segre,SeanConlan. 2023. Genomic characterization of the*C.*
*tuberculostearicum*species complex, a ubiquitous member of the human skin
microbiome. *bioRxiv* https://doi.org/10.1101/2023.06.16.545375
611
612

613   **Figure 1** Distribution of non-tuberculous Mycobacteria isolated from patients with
614   suspected pulmonary NTM in Hainan Island, China. Abbreviation：   NTM: non-tuberculous
615   Mycobacteria. RGM: rapidly growing mycobacteria; SGM: slowly growing mycobacteria.
616
617   **Figure 2** Phylogenetic tree of rpoB gene from 118 NTM using the neighbor-joining
618   method with MEGA11.0 software. Tree-scale 0.007 represents the evolutionary distance
619   unit, and Bootstrap values represents the self-expanding value, which is used to test the
620   calculated evolutionary Tree branch confidence.
621
622   **Figure 3** Distribution map of NTM in 14 cities and counties in Hainan Province
623   (Baisha, Baoting, Changjiang, Chengmai, Danzhou, Ding'an, Dongfang, Haikou, Ledong,
624   Lingao, Lingshui, Qionghai, Sanya, Wenchang).
625

Tree scale 0.009

Bootstrap values

1
0.8
0.6
0.4
0.2
0.04

NTM species

- Mycobacterium simiae
- Mycobacterium intracellulare
- Mycobacteroides abscessus
- Mycobacterium paraintracellulare
- Mycolicibacterium phlei
- Mycolicibacterium conceptionense
- Mycolicibacterium frederiksbergense
- Mycobacterium asiaticum
- Mycobacterium avium
- Mycolicibacterium phocaicum
- Mycobacterium colombiense
- Mycolicibacterium porcinum
- Mycolicibacterium vanbaalenii
- Mycobacterium novum
- Mycolicibacterium brisbanense
- Mycolicibacterium fortuitum
- Mycobacterium sherrisii
- Mycobacterium timonense
- Mycobacterium eburneum
- Mycolicibacterium bacteremicum
- Mycobacterium nebraskense
- Mycobacterium marseillense
- Mycolicibacter algericus
- Mycolicibacter sinensis

Region

- Danzhou
- Wenchang
- Changjiang
- Lingao
- Dingan
- Chengmai
- Lingshui
- Qionghai
- Dongfang
- Ledong
- Baisha
- Sanya
- Baoting
- Haikou

NTM species

Region

RGM

SGM

25 km